 - relapsed with documented evidence of relapse more than 12 months from completion of adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy with either an antiestrogen or an aromatase inhibitor for advancedmetastatic disease 